Pui Cheng, MD
Gynecologic Oncology · New Orleans, LANPI 1568554319
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $701, 6.7 times the $105 reported in 2019.
Across 67 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$337
- Merck$301
- AstraZeneca$239
- Eisai Inc.$167
- Astellas Pharma US Inc$129
- AbbVie$70
- plus $386 from 14 others
What the payments were for
- Food & beverage$1,60098%
- Education$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $337 |
| Merck | 13 | $301 |
| AstraZeneca | 9 | $239 |
| Eisai Inc. | 3 | $167 |
| Astellas Pharma US Inc | 5 | $129 |
| AbbVie | 4 | $70 |
| Scynexis, Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Boehringer Ingelheim | 1 | $33 |
| Mayne Pharma Commercial LLC | 1 | $30 |
| Clovis Oncology, Inc. | 2 | $28 |
| Caris MPI, Inc. | 1 | $28 |
| Pharmaand GmbH | 1 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Immunogen, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Coopersurgical, Inc. | 1 | $17 |
| Lupin Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$124
How this compares
Too few gynecologic oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $215 |
| Gabapentin | 36 | $174 |
| Ondansetron Hcl | 21 | $143 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in New Orleans
- Jacob EstesNew Orleans$16K
- Katrina WadeNew Orleans$8K
- Jessica ShankNew Orleans$4K
- David BarringtonNew Orleans$2K
- Diogo TorresNew Orleans$2K
- Richard KlineNew Orleans$257
- Patricia BralyCovington$130K
- Destin BlackShreveport$61K
- Andrew GreenShreveport$53K
- Amma AgyemangMetairie$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.